Guy Ungerechts

Heidelberg University — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index3.1kcitations107works2.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(84), CAR-T cell therapy research(49), Cancer Research and Treatments(35), Virology and Viral Diseases(28), Animal Virus Infections Studies(16)

Publications107 total

Oncolytic viruses as anticancer agents: clinical progress and remaining challenges
The Lancet·2025
GOBLET study: Results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +/- atezolizumab.
Journal of Clinical Oncology·2025· 2 cited
Data from Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
2024Open Access
Supplementary Data from Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
2024Open Access
611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors
Annals of Oncology·2024· 10 citedOpen Access
H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma
Cancers·2024· 2 citedOpen Access
An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
Journal of Clinical Oncology·2024· 3 cited
The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics
Pathogens·2024· 3 citedOpen Access
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
Journal of Clinical Oncology·2024· 1 cited
The Multifaceted Role of Protoparvoviruses in Human Cutaneous T Cell Lymphoma: From Candidate Causative Agents to Potential Oncolytic Virus Therapeutics
Preprints.org·2024· 1 citedOpen Access
1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Annals of Oncology·2023· 5 citedOpen Access
Onkolytische Viren zur Behandlung von Krebserkrankungen
BIOspektrum·2023Open Access
619P Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Annals of Oncology·2023· 1 cited
Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells
Pathogens·2023· 8 citedOpen Access
Supplementary Table 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 2 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Table 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Table 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Christine E. Engeland(19), Sascha Bossow(18), Dirk Jäger(15), Christoph Springfeld(14), Christof von Kalle(13), Mathias F. Leber(12), Christian Grossardt(9), Roberto Cattaneo(9), John C. Bell(7), Dirk M. Nettelbeck(7), Ulrich M. Lauer(7), Birgit Hoyler(7), Rūta Veinalde(6), Jean Rommelaere(6), Marie Frenzke(6), Michael Bitzer(6), Niels Halama(5), Christian J. Buchholz(5), Wolfgang J. Neubert(5), Karim Zaoui(4)